|Application ||WB, IHC-P, IF, E|
|Other Accession||NP_004946, 4826716|
|Calculated MW||Predicted: 50 kDa |
Observed: 53 kDa
|Application Notes||SLC29A1 antibody can be used for detection of SLC29A1 by Western blot at 1 - 2 µg/mL. Antibody can also be used for immunohistochemistry starting at 5 µg/mL. For immunofluorescence start at 20 µg/mL.|
|Target/Specificity||SLC29A1; SLC29A1 antibody is human specific. SLC29A1 antibody is predicted to not cross-react with other SLC29 proteins.|
|Reconstitution & Storage||SLC29A1 antibody can be stored at 4℃ for three months and -20℃, stable for up to one year.|
|Precautions||SLC29A1 Antibody is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||Mediates both influx and efflux of nucleosides across the membrane (equilibrative transporter). It is sensitive (ES) to low concentrations of the inhibitor nitrobenzylmercaptopurine riboside (NBMPR) and is sodium-independent. It has a higher affinity for adenosine. Inhibited by dipyridamole and dilazep (anticancer chemotherapeutics drugs).|
|Cellular Location||Basolateral cell membrane; Multi-pass membrane protein. Apical cell membrane; Multi-pass membrane protein. Cell membrane; Multi-pass membrane protein Note=Predominantly localized in the basolateral membrane in polarized MDCK cells|
|Tissue Location||Detected in erythrocytes (at protein level). Expressed in heart, brain, mammary gland, erythrocytes and placenta, and also in fetal liver and spleen|
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
SLC29A1 is a member of the equilibrative nucleoside transporter family which plays a key role in nucleoside and nucleobase uptake for salvage pathways of nucleotide synthesis (1,2). SLC29A1 is a transmembrane glycoprotein that localizes to the plasma and mitochondrial membranes and mediates the cellular uptake of nucleosides from the surrounding medium (3). As a nucleoside transporter, SLC29A1 plays an important role in the uptake of nucleoside-based anti-cancer drugs; polymorphisms of point mutations in the gene encoding this protein may affect the efficacy of these drugs (4).
Griffiths M, Beaumont N, Yao SY, et al. Cloning of a human nucleoside transporter implicated in the cellular uptake of adenosine and chemotherapeutic drugs. Nat. Med. 1997; 3:89-93.
Young JD, Yao SY, Baldwin JM, et al. The human concentrative and equilibrative nucleoside transporter families, SLC28 and SLC29. Mol. Aspects. Med. 34:529-47.
Mangravite LM, Xiao G, and Giacomini KM. Localization of human equilibrative nucleoside transporters, hENT1 and hENT2, in renal epithelial cells. Am. J. Physiol. Renal Physiol. 284:F902-10.
Zimmerman EI, Huang M, Leisewitz AV, et al. Identification of a novel point mutation in ENT1 that confers resistance to Ara-C in human T cell leukemia CCRF-CEM cells. FEBS Lett. 2009; 583:425-9.
If you have any additional inquiries please email technical services at firstname.lastname@example.org.